Vireo Growth Inc. (VREOF) stock
VREOFOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 11/30
$9.01+0.01 (+0.11%)
Close on Oct 19, 2026Market cap $443.48MP/E –Yield –
Vireo Growth ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Vireo Growth's ebitda for the twelve months ending Sep 30, 2026 was $36.36M, up 643.0% year over year. For fiscal 2025 it was $15.06M, down 6.5% from the year before. The highest annual figure on record is $16.10M in fiscal 2024.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.06M | -6.5% |
| FY2024 | Dec 31, 2024 | $16.10M | +19.7% |
| FY2023 | Dec 31, 2023 | $13.45M | – |
| FY2022 | Dec 31, 2022 | -$3.60M | – |
| FY2021 | Dec 31, 2021 | -$17.45M | – |
| FY2020 | Dec 31, 2020 | -$20.56M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $13.70M | +328.1% |
| Q2 FY2026 | Jun 30, 2026 | -$400.00K | – |
| Q1 FY2026 | Mar 31, 2026 | $13.00M | +400.0% |
| Q4 FY2025 | Dec 31, 2025 | $10.06M | – |
| Q3 FY2025 | Sep 30, 2025 | $3.20M | -28.7% |
| Q2 FY2025 | Jun 30, 2025 | -$700.00K | -110.9% |
| Q1 FY2025 | Mar 31, 2025 | $2.60M | -51.8% |
| Q4 FY2024 | Dec 31, 2024 | -$205.97K | -103.4% |
| Q3 FY2024 | Sep 30, 2024 | $4.49M | -31.3% |
| Q2 FY2024 | Jun 30, 2024 | $6.43M | – |
| Q1 FY2024 | Mar 31, 2024 | $5.39M | +327.3% |
| Q4 FY2023 | Dec 31, 2023 | $6.03M | +279.2% |
| Q3 FY2023 | Sep 30, 2023 | $6.52M | +945.0% |
| Q2 FY2023 | Jun 30, 2023 | -$364.39K | -133.6% |
| Q1 FY2023 | Mar 31, 2023 | $1.26M | – |
| Q4 FY2022 | Dec 31, 2022 | $1.59M | – |
| Q3 FY2022 | Sep 30, 2022 | $624.26K | – |
| Q2 FY2022 | Jun 30, 2022 | $1.09M | – |
| Q1 FY2022 | Mar 31, 2022 | -$6.90M | – |
| Q4 FY2021 | Dec 31, 2021 | -$7.42M | – |
| Q3 FY2021 | Sep 30, 2021 | -$3.34M | – |
| Q2 FY2021 | Jun 30, 2021 | -$2.52M | – |
| Q1 FY2021 | Mar 31, 2021 | -$4.16M | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.77M | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.53M | – |
| Q2 FY2020 | Jun 30, 2020 | -$11.25M | – |
| Q1 FY2020 | Mar 31, 2020 | -$6.01M | – |
See a number that looks wrong?